COVID-19 and the quality use of medicines: evidence, risks and fads.
作者信息
Roberts Darren M, Bennett Alexandra
机构信息
Departments of Clinical Pharmacology and Toxicology, and Renal Medicine and Transplantation, St Vincent's Hospital, Sydney.
St Vincent's Clinical School, University of New South Wales, Sydney.
出版信息
Aust Prescr. 2020 Jun;43(3):78-80. doi: 10.18773/austprescr.2020.031. Epub 2020 May 8.
Abstract
摘要
相似文献
1
COVID-19 and the quality use of medicines: evidence, risks and fads.2019冠状病毒病与药品合理使用：证据、风险与时尚潮流
Aust Prescr. 2020 Jun;43(3):78-80. doi: 10.18773/austprescr.2020.031. Epub 2020 May 8.
2
A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.关于2019年冠状病毒病对非洲全民健康覆盖所需基本药物和疫苗的可及性、安全性、质量及可负担性的潜在途径和影响的综述。
Global Health. 2021 Apr 8;17(1):42. doi: 10.1186/s12992-021-00666-8.
3
Medicines dispensing practice during the era of COVID-19 pandemic: a commentary.新冠疫情时代的药品配给实践：一篇评论
J Pharm Policy Pract. 2021 Jan 4;14(1):1. doi: 10.1186/s40545-020-00285-5.
4
Coronavirus disease-19 in environmental fields: a bibliometric and visualization mapping analysis.环境领域中的新型冠状病毒肺炎：文献计量与可视化图谱分析
Environ Dev Sustain. 2021;23(6):8895-8923. doi: 10.1007/s10668-020-01004-5. Epub 2020 Oct 6.
5
Availability of Internationally Controlled Essential Medicines in the COVID-19 Pandemic.新型冠状病毒肺炎大流行期间国际管制基本药物的可及性
J Pain Symptom Manage. 2020 Aug;60(2):e48-e51. doi: 10.1016/j.jpainsymman.2020.04.153. Epub 2020 May 7.
6
Medicines management at home during the COVID-19 pandemic: a qualitative study exploring the UK patient/carer perspective.新冠疫情期间居家的药品管理：一项探索英国家庭患者/照护者视角的定性研究
Int J Pharm Pract. 2021 Oct 18;29(5):458-464. doi: 10.1093/ijpp/riab050.
7
COVID-19 containment and its unrestrained impact on epilepsy management in resource-limited areas of Pakistan.COVID-19 防控措施及其对巴基斯坦资源有限地区癫痫管理的无限制影响。
Epilepsy Behav. 2020 Nov;112:107476. doi: 10.1016/j.yebeh.2020.107476. Epub 2020 Sep 25.
8
A dynamic risk assessment model to assess the impact of the coronavirus (COVID-19) on the sustainability of the biomass supply chain: A case study of a U.S. biofuel industry.一种用于评估冠状病毒（COVID-19）对生物质供应链可持续性影响的动态风险评估模型：以美国生物燃料行业为例
Renew Sustain Energy Rev. 2021 Nov;151:111574. doi: 10.1016/j.rser.2021.111574. Epub 2021 Aug 14.
9
[Health professionals facing the coronavirus disease 2019 (COVID-19) pandemic: What are the mental health risks?].面对2019冠状病毒病（COVID-19）大流行的卫生专业人员：心理健康风险有哪些？
Encephale. 2020 Jun;46(3S):S73-S80. doi: 10.1016/j.encep.2020.04.008. Epub 2020 Apr 22.
10
[Reconsidering the technical aspects and quality management background of faecal microbiota transplantation due to the novel coronavirus pandemic].[鉴于新型冠状病毒大流行重新审视粪便微生物群移植的技术方面和质量管理背景]
Orv Hetil. 2020 Nov 1;161(44):1858-1871. doi: 10.1556/650.2020.32023.
引用本文的文献
1
Egyptian perspectives on potential risk of paracetamol/acetaminophen-induced toxicities: Lessons learnt during COVID-19 pandemic.埃及对乙酰氨基酚所致毒性潜在风险的看法：新冠疫情期间的经验教训
Toxicol Rep. 2022;9:541-548. doi: 10.1016/j.toxrep.2022.03.035. Epub 2022 Mar 29.
2
[Not Available].[无可用内容]
FMC. 2021 Jan;28(1):40-56. doi: 10.1016/j.fmc.2020.10.005. Epub 2021 Jan 23.
3
Using Simulation to Teach Methods for Improving Patient Literacy about Medicines.利用模拟教学提高患者药物知识水平的方法
Pharmacy (Basel). 2020 Oct 18;8(4):192. doi: 10.3390/pharmacy8040192.
4
QUM and COVID-19 in young adults.年轻人中的QUM与新型冠状病毒肺炎
Aust Prescr. 2020 Aug;43(4):110. doi: 10.18773/austprescr.2020.038. Epub 2020 Aug 3.
5
Immunosuppression for COVID-19: repurposing medicines in a pandemic.用于治疗新冠肺炎的免疫抑制：在大流行中重新利用药物。
Aust Prescr. 2020 Aug;43(4):106-107. doi: 10.18773/austprescr.2020.037. Epub 2020 Jun 17.
本文引用的文献
1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
3
Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.心血管疾病与 COVID-19：澳大利亚和新西兰共识声明。
Med J Aust. 2020 Aug;213(4):182-187. doi: 10.5694/mja2.50714. Epub 2020 Jul 31.
4
Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic.自我及他人的道德用药原则：新冠疫情期间的羟氯喹
Aust Prescr. 2020 Jun;43(3):76-77. doi: 10.18773/austprescr.2020.030. Epub 2020 Apr 22.
5
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。
Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.
6
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
7
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
8
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
9
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.高剂量与低剂量磷酸氯喹作为辅助治疗对住院的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染患者的影响：一项随机临床试验。
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
10
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
Zotero 插件